Twin Tree Management
ACAD icon

Twin Tree Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Twin Tree Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-81,700
Closed -$1.51M – 1313
2024
Q1 		$1.51M Buy
+81,700
New +$2.02M ﹤0.01% 1019

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Twin Tree Management's ACAD Position: Q2 2024 in Review

Twin Tree Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 76,887 shares — an estimated $1.42M sold.

Twin Tree Management first reported a position in ACAD in Q1 2019 and held it in 3 quarters. The position peaked at $1.42M in Q1 2024. 265 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

  • Twin Tree Management reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Twin Tree Management sold 76,887 Acadia Pharmaceuticals shares in Q2 2024, an estimated $1.42M.
  • Twin Tree Management first reported a position in Acadia Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Twin Tree Management's Acadia Pharmaceuticals position peaked at $1.42M in Q1 2024.
  • 265 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on Twin Tree Management's 13F filing for Q2 2024, filed 13 Aug 2024.